ITeos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 07, 2023 at 07:07 am EST
Share
iTeos Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 32.24 million compared to net income of USD 0.991 million a year ago. Basic loss per share from continuing operations was USD 0.9 compared to basic earnings per share from continuing operations of USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.9 compared to diluted earnings per share from continuing operations of USD 0.03 a year ago.
For the nine months, revenue was USD 12.6 million compared to USD 213.73 million a year ago. Net loss was USD 82.09 million compared to net income of USD 76.2 million a year ago. Basic loss per share from continuing operations was USD 2.3 compared to basic earnings per share from continuing operations of USD 2.14 a year ago. Diluted loss per share from continuing operations was USD 2.3 compared to diluted earnings per share from continuing operations of USD 2.01 a year ago.
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.
ITEOS THERAPEUTICS, INC. 
